Adaptimmune to 'redefine' itself as a sarcoma biotech, cuts a third of staffers

Adaptimmune is slashing its headcount as part of a broader company restructuring aimed at saving $300 million over the next few years through 2028. The company said it will axe 33% of its employees in ...